Pacira Pharma (PCRX) Tops Q2 EPS by 17c, Beats on Revenues; Offers FY18 Revenue Outlook Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Pacira Pharmaceuticals (PCRX) PT Raised to $50 at RBC Capital
August 3, 2018 7:56 AM EDTRBC Capital raised its price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $50.00 (from $44.00) while maintaining a Outperform rating.
... MoreNeedham & Company Upgrades Pacira Pharmaceuticals (PCRX) to Buy; 'All Signs Point to a Significant Exparel Growth Inflection'
August 3, 2018 7:27 AM EDTNeedham & Company upgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Hold to Buy with a price target of $54.00.
Analsyt Serge Belanger commented, " Exparel's strong 2Q18 performance ($80.4MM, +15%Yr/ Yr) appears to be accelerating with sales growth of 16%Yr/Yr in May and 18%Yr/Yr... More
Pacira Pharmaceuticals (PCRX) PT Raised to $53 at Seaport Global Securities
August 3, 2018 7:23 AM EDTSeaport Global Securities raised its price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $53.00 (from $48.00) while maintaining a Buy rating.
... MorePacira Pharmaceuticals (PCRX) PT Raised to $40 at BMO Capital
August 3, 2018 6:57 AM EDTBMO Capital raised its price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $40.00 (from $34.00) while maintaining a Market Perform rating.
Analsyt Gary Nachman commented, "PCRX reported 2Q18 non-GAAP revenue of $81mmabove BMO/consensus $77mm/$76mm, and EPS of $0.24 above BMO/consensus $0.09/$0.07. Solid 2Q... More
Pacira Pharmaceuticals (PCRX) PT Raised to $50 at Barclays
August 3, 2018 5:09 AM EDTBarclays raised its price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $50.00 (from $40.00) while maintaining a Overweight rating.
... More